此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

2026年11月12日 更新者:Case Comprehensive Cancer Center

GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.

研究概览

详细说明

Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.

研究类型

介入性

注册 (估计的)

150

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Laura Bukavina, MD, MPH, MSc
  • 电话号码:(216) 444-6043
  • 邮箱:bukavil2@ccf.org

研究联系人备份

  • 姓名:Myra Krnac
  • 电话号码:(216)444-1047
  • 邮箱:krnacm@ccf.org

学习地点

    • Ohio
      • Cleveland、Ohio、美国、44106
        • Cleveland Clinic Foundation
        • 接触:
          • Laura Bukavina, MD, MPH, MSc
          • 电话号码:(216) 444-6043
          • 邮箱:bukavil2@ccf.org
        • 首席研究员:
          • Laura Bukavina, MD, MPH, MSc

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
  • Planned for radical cystectomy with curative intent.
  • Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
  • Adequate organ function as defined by standard laboratory criteria.
  • Ability to understand and provide written informed consent.

Exclusion Criteria:

  • Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
  • Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
  • Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
  • Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:ctDNA-negative MIBC

There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments.

Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Recurrence free survival (RFS)
大体时间:2 years

RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first.

2 years

次要结果测量

结果测量
措施说明
大体时间
Overall survival (OS)
大体时间:at 2 years

Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

at 2 years
Overall survival
大体时间:at 5 years

Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

at 5 years
Rate of pathological complete response (pCR)
大体时间:at day 0

To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy.

at day 0
Rates of surgical morbidity
大体时间:up to 4 weeks

To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

up to 4 weeks
Rates of complications
大体时间:up to 4 weeks

To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

up to 4 weeks
Positive predictive value
大体时间:days -42 to 0

To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement

days -42 to 0
Negative predictive value
大体时间:days -42 to 0

To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement

days -42 to 0

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Laura Bukavina, MD, MPH, MSc、The Cleveland Clinic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2029年1月1日

研究完成 (估计的)

2032年12月1日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

There is not currently an intention or plan to share IPD

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅